Health & Fitness
Health and Fitness
Health and Fitness
Tue, January 20, 2009
Mon, January 19, 2009
Fri, January 16, 2009 Advaxis Files 8-K on European Patent Appeal
NORTH BRUNSWICK, N.J.--([ BUSINESS WIRE ])--Advaxis Incorporated (OTCBB: ADXS) has filed an 8-K with respect to its favorable appeal ruling in the European Patent Office Board of Appeals in Munich, Germany.
The ruling:
- set aside a patent challenge filed by Anza Therapeutics, Inc., formerly Cerus Corp (NASDAQ: CERS)
- confirmed that Dr. Yvonne Paterson had invented the first bacterium bioengineered to deliver a tumor specific antigen for the purpose of treating patients with cancer
- reestablished the Trustees' of the University of Pennsylvania and its exclusive licensee, Advaxis, dominant patent position in Europe to recombinant Listeria for treating cancer
There can be no further appeals to this decision.
About Advaxis, Incorporated
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing attenuated live Listeria-based vaccines that deliver engineered tumor antigens, which safely stimulate multiple simultaneous immunological mechanisms to fight cancer.
Advaxis' lead Listeria vaccine candidate, Lovaxin-C, targets human papilloma virus (HPV)-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I clinical trial of Lovaxin-C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia (CIN). The Lm platform also has applications in the fields of infectious disease and autoimmune disorders.
For further information on the Company, please visit: [ www.advaxis.com ].
About the Lovaxin-C Vaccine
Advaxis' technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Bioengineered Listeria that are attenuated and secrete Advaxis' proprietary fusion protein, have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.
Advaxis' Listeria-based technology is based on over fifteen years of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Company's proprietary antigen fusion protein technology, stimulates innate immunity, both arms of the adaptive cellular immune system, suppresses regulatory T-cells that inhibit many vaccines in the function of activated tumor-killing cells and has other anti-tumor effects.
Unlike prophylactic vaccines, Lovaxin-C was designed to treat women who have already developed cervical cancer as a result of contracting an HPV infection, which is the most prevalent sexually transmitted disease in the US. Current products on the market are ineffective in treating HPV-infected women.
For further information on Lovaxin-C, please visit: [ www.advaxis.com/lc.htm ].
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
